C4 Therapeutics Appoints Paige Mahaney, Ph.D., as Chief Scientific Officer and Announces Retirement of Stewart Fisher, Ph.D.

Company Leadership Changes - Paige Mahaney, PhD, appointed as Chief Scientific Officer (CSO) of C4 Therapeutics, effective October 28, 2024, bringing over 25 years of pharmaceutical and biotech experience [1] - Stewart (Stew) Fisher, PhD, current CSO, will retire and serve as senior scientific advisor until December 31, 2024, and as a consultant through the end of 2025 [1] Paige Mahaney's Background - Over 25 years of experience in pharmaceutical executive leadership, with expertise in discovery research, development, and building clinical portfolios across various disease indications and treatment modalities [2] - Previously served as Senior Vice President and Corporate Head of Drug Discovery at Exelixis, Inc, where she advanced multiple candidates toward investigational new drug applications and clinical trials, including USP-1 inhibitor XL309 and PKMYT1 inhibitor XL495 [2] - Spent over 10 years at Boehringer Ingelheim Pharmaceuticals, Inc, focusing on pipeline expansion and discovery, contributing to the advancement of several investigational assets in oncology, immunology, cardiometabolic, inflammation, respiratory, and orphan diseases [2] Stewart Fisher's Contributions - Joined C4 Therapeutics in 2016 and served as CSO since 2018, supporting the development of the TORPEDO® platform and leading the creation of a library of over 10,000 Cereblon ligands from over 200 unique scaffolds [3] - Spearheaded the identification, characterization, and optimization of novel, selective, orally bioavailable BiDAC™ and MonoDAC™ degraders, resulting in six development candidates delivered to the clinical pipeline [3] - Advanced three novel degraders into clinical trials and partnered with global pharmaceutical companies to extend the reach of targeted protein degradation [4] C4 Therapeutics Overview - Clinical-stage biopharmaceutical company focused on advancing targeted protein degradation science to create transformative medicines [6] - Progressing targeted oncology programs through clinical studies and leveraging the TORPEDO® platform to design and optimize small-molecule medicines for difficult-to-treat diseases [6] - Degrader medicines designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, potentially overcoming drug resistance and undruggable targets [6]